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MoCAIdiopathic Parkinson3s disease (IPD) is the secondmost common neurodegenerative disease, yet effective disease
modifying treatments are still lacking. Neurodegeneration involves multiple interacting pathological pathways.
The extent to which neurovascular mechanisms are involved is not well deﬁned in IPD. We aimed to determine
whether novel magnetic resonance imaging (MRI) techniques, including arterial spin labelling (ASL) quantiﬁca-
tion of cerebral perfusion, can reveal altered neurovascular status (NVS) in IPD.
Fourteen participants with IPD (mean ± SD age 65.1 ± 5.9 years) and 14 age and cardiovascular risk factor
matched control participants (mean ± SD age 64.6 ± 4.2 years) underwent a 3T MRI scan protocol. ASL images
were collected before, during and after a 6 minute hypercapnic challenge. FLAIR images were used to determine
white matter lesion score. Quantitative images of cerebral blood ﬂow (CBF) and arterial arrival time (AAT) were
calculated from the ASL data both at rest and during hypercapnia. Cerebrovascular reactivity (CVR) images were
calculated, depicting the change in CBF and AAT relative to the change in end-tidal CO2.
A signiﬁcant (p = 0.005) increase in whole brain averaged baseline AAT was observed in IPD participants
(mean ± SD age 1532 ± 138 ms) compared to controls (mean ± SD age 1335 ± 165 ms). Voxel-wise analysis
revealed this to be widespread across the brain. However, there were no statistically signiﬁcant differences in
white matter lesion score, CBF, or CVR between patients and controls. Regional CBF, but not AAT, in the IPD
group was found to correlate positively with Montreal cognitive assessment (MoCA) scores. These ﬁndings pro-
vide further evidence of alterations in NVS in IPD.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).rrival time; AD, Alzheimer’s dis-
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Idiopathic Parkinson3s disease (IPD) is the second most common
neurodegenerative disorder, affecting 1–2% of the population over the
age of 65, with the incidence increasing steeply with age (Van Den
Eeden et al., 2003). Progression is variable and difﬁcult to predict, but
IPD is often associated with signiﬁcant disability. Treatment remains
symptomatic, with an absence of effective disease modifying or neuro-
protective agents.
Alterations in neurovascular status (NVS) – including measures of
cerebral hemodynamic function as well as more conventional clinical
and radiological measures of cerebrovascular disease (CVD) – might
be expected in IPD for two principal reasons. Firstly, neurodegeneration
is considered to comprise multiple interacting pathological pathways
(Collins et al., 2012). Recently there has been considerable interest
in the disturbance of neurovascular unit (NVU) function and the
‘neurovascular model’ of neurodegeneration (Grammas et al., 2011;
Zlokovic, 2008). The NVU is a complex, metabolically active system ofthe CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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altered NVU function is primary or secondary to neurodegeneration, or
even attributable to the effect of pharmacotherapy, remains unclear.
Secondly, as IPD is strongly associatedwith ageing, an increased burden
of comorbid CVDmight be expected, but the evidence is somewhat con-
ﬂicted probably on account of varying study designs and endpoints
(Morley and Duda, 2012). Currently, the extent to which NVS is altered
in IPD is poorly deﬁned.
There is also substantial heterogeneity within IPD with respect to
clinical phenotype, including motor and non-motor features and it is
possible that differences in NVS might be inﬂuential in these differing
phenotypes (Lee et al., 2009). Tremor dominant (TD) and postural in-
stability and gait disorder (PIGD) phenotypes are recognised, based on
the predominantmotor features (Jankovic et al., 1990). Non-motor fea-
tures (in particular neuropsychiatric and cognitive dysfunction) have
been reported in a signiﬁcant proportion of IPD patients; with cognitive
decline being associated with worse motor and non-motor features
(Aarsland et al., 1999; Hu et al., 2014). Studies suggest distinct clinical
courses and even variable involvement of the dopaminergic system
and other pathways between phenotypes (Eggers et al., 2012; Mito
et al., 2006).
Magnetic resonance imaging (MRI) can provide valuable measures
of NVS, such as white matter lesion (WML) burden and cerebral blood
ﬂow (CBF). Arterial spin labelling (ASL) employs magnetically labelled
endogenous arterial blood water to quantify cerebral perfusion. ASL
can also measure arterial arrival time (AAT), the time taken for blood
to travel from the labelling slab to the tissue of interest (Wang et al.,
2003; Zappe et al., 2007). AAT is longest in distal branches, especially
in border zone (or watershed) areas (Hendrikse et al., 2008; Petersen
et al., 2006). Alterations in resting state AAT are considered likely to re-
ﬂect chronic arteriolar vasodilation or collateral ﬂow (Derdeyn et al.,
2002; Farkas and Luiten, 2001). Cerebrovascular reactivity (CVR) can
be measured by combining ASL with a hypercapnic challenge. CVR
reﬂects the capacity of the blood vessels to dilate in response to a hyper-
capnic challenge and can be used as a measure of brain vascular reserve
(Hajjar et al., 2010).
We hypothesise that NVS is altered in IPD. This was tested by com-
paring MRI measurements of NVS between a group of people with IPD
and age and cardiovascular risk matched controls. In addition MRI im-
ages were correlated against cognitive and neuropsychiatric scores to
determine any association between NVS measurements and such non-
motor features of IPD.
2. Methods
2.1. Participants
Relevant approvals were obtained including ethics (North West —
Preston Research Ethics Committee), research governance and local uni-
versity approvals. Eligibility criteria for IPD participants were a clinical
diagnosis of IPD fulﬁlling the UK Parkinson3s Disease Society (UKPDS)
Brain Bank (BB) criteria (http://www.ncbi.nlm.nih.gov/projects/gap/
cgi-bin/GetPdf.cgi?id=phd000042)without known clinical CVD (nohis-
tory of transient ischaemic attack or stroke) or dementia (Emre et al.,
2007) or radiological evidence of large vessel cortical/subcortical infarct
N1.5 cm. Control participants (without IPD or above exclusion criteria)
were matched for age and cardiovascular risk factors. All participants
were required to providewritten informed consent and had the capacity
to do so. All underwent a scan protocol on a 3T Philips Achieva MRI sys-
tem using an 8 channel head coil at Salford Royal Hospital. Involuntary
movements in participants were minimised using padding within the
head coil. All participants were scanned ‘ON’ their medications. IPD phe-
notype was assessed using the Uniﬁed Parkinson3s Disease Rating Scale
(UPDRS) (http://www.etas.ee/wp-content/uploads/2013/10/updrs.pdf)
during the scan visit. Participants were further classiﬁed into three sub-
types (TD, PIGD, and intermediate) by Jankovic3s method (Jankovicet al., 1990). Disease severity was measured using the Hoehn and Yahr
rating scale (Hoehn and Yahr, 1967). No alterations were made to the
participants3 medications for the study protocol. Routine clinical
baseline data were also recorded and the levodopa equivalent
doses (LEDD) calculated (Tomlinson et al., 2010). A battery of clinical
scales was administered, including the Montreal Cognitive Assessment
(MoCA) (http://www.MoCAtest.org), the O3Sullivan brief cognitive as-
sessment for participants with cerebral small vessel disease
(O3Sullivan et al., 2005), the Lille apathy rating scale (LARS) (Sockeel
et al., 2006), the Hamilton depression scale (HAM-D) (Muller and
Dragicevic, 2003) and the neuropsychiatric inventory (NPI) psychosis
subscale (Fernandez et al., 2008). Demographics and clinical data
were compared between IPD and control participants using the unpaired
Student t-test with p-value set at b0.05.
2.2. MRI protocol
A T2-weighted FLAIR image was acquired with the following
parameters: TR 11 s, TI 2.8 s, TE 120 ms, in-plane resolution of
0.45 mm, 30 axial slices of 4 mm thickness with 1 mm gap covering
the whole brain. A Look-Locker ASL sequence was used (Gunther
et al., 2001), with STAR labelling (Edelman et al., 1994) and 4 readout
times of 800, 1400, 2000, and 2600 ms, TR: 3500 ms; TE 22 ms; ﬂip
angle 40°; 3.5 × 3.5 × 6 mm voxels with a 1 mm gap between slices;
15 slices covering the cerebrum but not the cerebellum with bipolar
‘vascular crusher’ gradients added to dephase fast ﬂowing spins and
so remove large vessel signal. The labelling slab was 15 cm with a
10 mm gap between the labelling and imaging regions. 112 pairs of
labelled and control images were collected, with scan duration approx-
imately 13min. To allow quantiﬁcation of CBF an additional scanwas ac-
quired with TR = 10 s and 15 read-out times (from 800 to 9200 ms) in
order to estimate the equilibriummagnetisation of the brain. An addition-
al echo planar image (EPI) was collected with the same slice positioning
and the same voxel dimensions but with TE = 35 ms to give typical
fMRI contrast for registration and normalisation purposes. A 3D T1-
weighted image with 1 mm isotropic resolution was also collected.
During the ASL acquisition a CO
2
(hypercapnic) challenge was car-
ried out. After 5min of breathing roomair (fromwhich thebaseline per-
fusion images were extracted) there followed 6 min of hypercapnia,
administered using a non-rebreathing circuit using the Fenn and Craig
technique (Fenn and Craig, 1963) and a ﬁnal 2 min of return to room
air. This method involves a thin stream of gas (79% CO
2
balanced with
21% O
2
) being delivered through larger tubing allowing it to mix with
room air. This mixture then passes through a 3-way valve which directs
it to a ﬁlter and a mouth piece (Vidyasagar et al., 2013). End-tidal CO
2
(ETCO
2
) and O
2
were continuously monitored using Powerlab (LabChart7
V7.2.1, 2011) and the CO
2
ﬂow-rate was altered to ensure all participants
reached an increased end tidal level approximately 1% above their base-
line ETCO
2
. Prior to each scanning session the gas analysers were calibrat-
ed using a canister of gas with known concentrations of 5.03% CO
2
and
21.0% O
2
, each participant also had a trial session of inhaled gas to allow
them to become accustomed to the apparatus, this also provided an op-
portunity to assess an appropriate ﬂow rate required to induce a 1%
change in ETCO2.
2.3. Data analysis
WML burden was assessed semi-quantitatively using visual rating
scales (Fazekas et al., 1993;Wahlund et al., 2001). Between group com-
parisons were made using Student3s unpaired t test analysis. ASL data
were analysed using in-houseMATLAB (Mathworks, MA, USA) routines
using a single blood compartmentmodel, adapted for Look-Locker read-
out (Parkes L.M., 2012). Further details of the ASLmodeling are given in
the appendix.
Baseline CBF and AAT maps were calculated using the ﬁrst 5 min of
ASL data, during breathing of air. CVR maps were calculated using
Table 2
Key measurement items from the UPDRS. Scores: bradykinesia (0–36), tremor (0–32),
rigidity (0–20), PIGD (0–20).
UPDRS item PIGD sub-score TD sub-score
Bradykinesia
Mean (SD)
6.2 (3.7) 6.1 (0.2)
Tremor
Mean (SD)
1.8 (2.1) 11.5 (4.7)
Rigidity
Mean (SD)
8.5 (3.8) 8.2 (5.4)
PIGD
Mean (SD)
12.5 (3.9) 1.5 (1.0)
3S. Al-Bachari et al. / NeuroImage: Clinical 6 (2014) 1–8subtraction images of CBF and AAT between periods of air (5 min) and
hypercapnia (last 5 min, omitting the ﬁrst minute of hypercapnia to
allow equilibrium to be reached) and dividing these by the value of
ΔETCO
2
on an individual basis. Whole brain values for CBF, AAT, CVR
CBF
(% CBF change/ΔETCO
2
) and CVR
AAT
(ΔAAT/ΔETCO
2
) were calculated
using a simple threshold mask based on the ASL control images on an
individual basis. Differences between IPD and control participants for
CBF, AAT and all CVR measures were tested using Student3s t-tests in
Excel. Differences between IPD and control participants for WML bur-
den as measured by the visual rating scales were tested using Fisher3s
exact test in SPSS, taking into account the non-parametric nature of
the scales and small sample sizes. Linear regression was used to assess
whether WML burden could predict CBF and AAT using WML burden
as a categorical variable in regression.
Voxel-wise analysis was also performed using the SPM8 PET toolbox
(http://www.ﬁl.ion.ucl.ac.uk/spm/) to compare CBF, AAT and CVRmaps
between IPD and control participants (phenotype speciﬁc differences
were not analysed due to the small sample sizes). Image pre-processing
in SPM included (1)motion correction, (2) registration and normalisation
of the EPI image to the EPI template within SPM, and application of this
procedure to the perfusion maps, and (3) spatial smoothing of the nor-
malised images using a 12 mm full-width-half-maximum kernel. CBF
maps were corrected for atrophy using the same method as Johnson
et al. (2005) according to the proportion of graymatter andwhite matter
in each voxel, obtained from the segmented T1-weighted image. Voxel-
wise comparisons of CBF, AAT, CVR
CBF
, and CVR
AAT
between the IPD and
control groups were carried out using a two-sample unpaired t-test
(unequal variances). Regions were considered signiﬁcant at a p value
of b0.001 uncorrected, with a minimum cluster size of 100 voxels (at
the re-sampled voxel size of 2 mm isotropic), which was felt sufﬁcient
to avoid type II errors in view of the exploratory nature of the study
(Lieberman and Cunningham, 2009). Further analysis using family-
wise error (FWE) correction for multiple comparisons at the cluster
level was performed (using Gaussian Radom Field Theory as employed
in SPM8). In addition, voxel wise regression of CBF and AAT against
MoCA and HAM-D scores was performed within both the IPD and con-
trol groups separately.3. Results
3.1. Participants
Fourteen IPD participants (mean± SD age 65.1 ± 5.9 years) and 14
control participants (mean ± SD age 64.6 ± 4.2 years) were enrolled
into the study. Six IPD participants were assigned to the PIGD subgroup
and 6 to the TD subgroup and 2were intermediate (Table 1 and 2). Thir-
teen IPD and all 14 control participants completed the full scanning pro-
tocol (ASL data were lacking for 1 IPD participant due to difﬁculties in
tolerating the set-up of the gas apparatus in the scanner). All partici-
pants showed the expected increase in CBF and reduction in AAT with
the hypercapnic challenge due to induced cerebrovasodilation (Hajjar
et al., 2010). Two further IPD and 2 control participants were excluded
from CVR analysis as theΔETCO
2
gas response was outside the expectedTable 1
Demographics and clinical characteristics of the study group.
Controls
(n = 14)
IPD
(n = 14)
N (female: male) 4:10 6:9
Age, years: mean (± SD); [range] 64.6 (4.2); [58-71] 65.1 (5.9); [54
No. of cardiovascular risk factors: mean (SD) 0.9 (1.0) 1.4 (1.4)
No. of other comorbidites: mean (SD) 0.43 (0.65) 0.9 (1.03)
Disease duration, years: mean (SD) n/a 9.2 (6.0)
Hoehn and Yahr stage ON: mean (SD) n/a 2.5 (1.1)
LEDD score: mean (SD) n/a 638 (353)limits (4–12 mm Hg). Twelve IPD (6 PIGD, 5 TD) and 13 control partic-
ipants completed the clinical scales.
3.2. Baseline CBF and AAT
Whole brain baseline CBF did not differ between the IPD and control
groups (Table 3a). The voxel-wise analysis did reveal one region of
lower CBF in patients compared to controls (at p b 0.001minimum clus-
ter size 100 voxels) in the right parietal lobe supramarginal gyrus near
the angular gyrus (Talairach coordinates [16 −80 34], cluster size
231 voxels, peak t-value 3.8, peak p-value 0.0004). There were no
regions of signiﬁcant hyperperfusion in the IPD group compared to
controls.
Whole brain baseline AAT was signiﬁcantly prolonged in IPD partic-
ipants compared to controls (Table 3a). Voxel-wise analysis revealed
widespread regions of signiﬁcantly increased baseline AAT in the IPD
group compared to controls, particularly in the frontal and temporal re-
gions at p b 0.001 minimum cluster threshold 100 voxels (Fig. 1b and
Table 4). Two of these regions survive FWE correction (Fig. 1c). There
were no regions in the brain where AAT was signiﬁcantly shorter in
the IPD group than in the control group. A mean difference map of
AAT between patients and controls was created to further shed light
on the distribution of the prolonged AAT; this revealed bilateral, diffuse
increases in AAT in the IPD group compared to controls (Fig. 1a).
3.3. CVR measures
Whole brain measures of CVR
CBF
or CVR
AAT
did not differ between IPD
and control participants. Voxel-wise analysis did not reveal any regions
of statistically signiﬁcant differences in these measurements between
the groups.
3.4. WML burden
To test for differences in WML score Fisher’s exact test was used,
combining scores into categories (0–1) and 2 where appropriate since
themajority of patients scored 1 or 2. The results showed no association
between any of theWML scores andwhether a participant has IPD,with
p-values as given in Table 3b. There were no statistically signiﬁcant cor-
relations between the WML burden (Wahlund scale) and CBF or AAT.p value (IPD vs control) PIGD (n = 6) Tremor (n = 6)
n/a 4:2 0:6
-75] 0.7 65.5 (4.6); [61-72] 66.2 (0.6); [54-75]
0.3 0.8 (1.0) 2 (1.5)
0.2 1 (0.9) 0.8 (1.3)
n/a 10.8 (4.8) 5.2 (3.0)
n/a 3.2 (1.1) 1.8 (0.6)
n/a 750 (453) 488 (347)
Table 3a
Whole brain CBF, AAT and CVR measurements.
Control group (n = 14) mean ± SD IPD group (n = 13) mean ± SD p value (IPD vs controls)
Baseline CBF (ml/min/100 ml) 38.0 ± 9.3 35.3 ± 5.8 0.5
Baseline AAT (ms) 1335 ± 165 1532 ± 138 0.005
CVR_CBF (%/Δmm Hg) 2.2 ± 2.9 4.0 ± 2.9 (n = 13) 0.2
CVR_AAT (Δms/Δmm Hg) −21.5 ± 7.1 −15.3 ± 11.2 (n = 13) 0.2
Table 3b
WML rating scales. PVH, periventricular hyperintensity; DWMH, deep white matter hyperintensity.
Score Control group (n = 14) number (%) IPD group (n = 14) number (%) p value (IPD vs controls)
Wahlund 0 or 1 12 (85.7%) 8 (57.1%) 0.2
2 2 (14.3%) 6 (42.9%)
Fazekas PVH 1 11 (78.6%) 10 (71.4%) 1.0
2 3 (21.4%) 4 (28.6%)
Fazekas DWMH 0 or 1 12 (85.7%) 9 (65.3%) 0.4
2 2 (14.3%) 5 (35.7%)
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Results of the clinical scales are shown in Table 5. The IPD group
(mean±SD, score 8.5±2.5) scored signiﬁcantly lower than the controlFig. 1.Regions of prolonged arrival time in IPD compared to controls. a) Arrival time differencem
map obtained by comparison of AAT between the IPD group and controls thresholded to p b 0
p b 0.001 FWE-correctedwithminimumcluster size 100 voxels. Thus displaying positive t value
of decreased AAT).group (mean± SD score 10.8± 2.7, p= 0.03) in the digit symbol substi-
tution test (DSST). Six IPDparticipants (4 PIGD, 2 TD) but only one control
participant met criteria for mild cognitive impairment as reﬂected by
a score of ≤25 on the MoCA tool. Three IPD participants (2 PIGD, 1ap created by subtraction ofmean AAT in controls frommeanAAT in patients. b) t statistic
.001 uncorrected, minimum cluster size 100 voxels and c) t statistic map thresholded at
s, representing increasedAAT in the IPD group compared to controls (therewere no regions
Table 4
Regions of signiﬁcantly longer AAT in the IPD group compared to controls at p b 0.001, cluster size 100.
Region Cluster size Cluster p (FWE-cor) Peak t value Peak p (uncor) Peak MNI coordinates
L inferior frontal gyrus extending to sub-gyral region 839 0.02
5.2
b0.0001 −32 38 10
4.7 b0.0001 −34 24 8
4.4 b0.0001 −32 16 14
L middle TL extending to large sub gyral region 2327 b0.0001 5.1 b0.0001 −42−36−2
4.7 b0.0001 −42−46 6
4.7 b0.0001 −58−6−6
R middle temporal gyrus 110 0.8 4.6 b0.0001 64−38−8
L TL middle temporal gyrus 104 0.8 4.5 b0.0001 −66−34−12
L caudate body 101 0.8 4.5 b0.0001 −14 16 12
L cerebrummiddle frontal gyrus 140 0.7 4.4 b0.0001 −32 56−8
3.9 0.0004 −40 52−6
R inferior frontal gyrus 100 0.8 4.1 0.0002 −46 40 6
R TL superior to transverse gyrus 119 0.8 4.0 0.0002 36−34 10
3.7 0.0005 50−38 16
3.7 0.0005 46−34 6
R anterior cingulate 153 0.7 3.9 0.0003 14 40 10
3.9 0.0003 8 46 6
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Ham-D scale, whereas all control participants fell within the ‘not de-
pressed’ range on this scale. All participants completed the trail making
test part B (TMT-B) except for one IPD (PIGD group) and one control
participant. Neither group exhibited signiﬁcant apathy or any features
of psychosis as per the clinical scales.
Voxel-wise analysis using linear regressionwas performed to identi-
fy potential regional correlations between MOCA and HAM-D scores,
with both CBF and AAT. Reduced CBF mainly in the parietal regions
was found to correlate with reduced MoCA score (Table 6, Fig. 2) in
the IPD group only. To help verify the statistical threshold used, MoCA
scores of the IPD participants were shufﬂed randomly and the voxel-
wise regression analysis was repeated. No regions of signiﬁcant correla-
tion were found, conﬁrming the validity of our ﬁndings. There were no
regions of signiﬁcant correlation of MoCA score and AAT in either of the
two study groups. In addition HAM-D scores did not correlate with ei-
ther CBF or AAT in either the IPD or control group.
4. Discussion
We hypothesised that NVS is altered in IPD, which may be a reﬂec-
tion of the neurodegenerative process or due to comorbid CVD. The
two key ﬁndings of this study support this notion. We revealed diffuse
AAT prolongation in the IPD group compared to healthy control partic-
ipants and signiﬁcant regional correlations between MoCA scores and
CBF in the IPD group only.
To our knowledge, the prolonged AAT in the IPD group compared to
controls has not been previously reported. Although the differences ap-
pear predominantly in the right hemisphere the mean difference maps
suggest prolonged AAT is more diffuse (Fig. 1). It is possible to attribute
prolonged AAT to any factorwhich increases path length or decreases the
velocity of ﬂow i.e. diameter and resistance of vessels and characteristicsTable 5
Clinical scales and scores.
Controls (n = 13) IPD (n = 12)
HAM-D: mean (SD) 2.6 (2.4) 5.3 (5.4)
LARS: mean (SD) −26.3 (5.2) −25.3 (3.3)
DS: mean (SD) 9.5 (2.8) 11.4 (2.9)
DSST: mean (SD) 20.8 (2.7) 8.5 (2.5)
FAS VF: mean (SD) 52.3 (33.2) 49.0 (25.3)
TMT-B: mean (SD) 96.7 (40.8) 103.9 (40.8)
MoCA: mean (SD) 28.3 (3.0) 26.3 (3.0)
HAM-D, Hamilton depression scale; LARS, Lille apathy rating scale; DS, digit span; DSST, digit sy
cognitive assessment.of the circulating blood (Liu et al., 2012). Several other studies have re-
ported on AAT in non-PD populations with various reasons proposed.
For example, prolonged AAT has been noted in studies of ageing (Liu
et al., 2012), presumably related to age driven structural cerebrovascular
changes such as increased vessel tortuosity, increased rarefaction and
arteriolar wall damage (Chen et al., 2012; Wolk and Detre, 2012). AAT
prolongation in multiple sclerosis has been attributed to widespread
inﬂammation or chronic vasodilation of the resistance vessels (Paling
et al., 2014). A study in AD revealed prolonged AAT and hypoperfusion
in the left inferior frontal and middle cingulate gyri (Mak et al., 2012).
Lastly, stroke and TIA studies have attributed AAT prolongation to the re-
cruitment of collateral pathways in large artery stenosis with, in some
cases, preserved perfusion (Chalela et al., 2000; MacIntosh et al., 2010b;
Zaharchuk, 2011).
We did not ﬁnd differences in CBF between the IPD group and con-
trols at the p b 0.001, minimum cluster size 100 voxels, yet at the
more lenient threshold of p b 0.005, regions of hypoperfusion in the
left cuneus in the IPD group were revealed. This perfusion deﬁcit is in
keeping with both ASL and positron emission tomography (PET)
studies in IPD which have found a similar pattern of hypoperfusion
and hypometabolism in IPD patients compared to healthy controls
with signiﬁcant correlation between PET and ASL perfusion patterns
(Borghammer et al., 2010; Fernandez-Seara et al., 2012; Kamagata et al.,
2011;Ma et al., 2010;Melzer et al., 2011). These studies consistently re-
vealed bilateral hypoperfusion in the occipital lobe (including the
cuneus) as well as the posterior parietal regions, with variable patterns
in the frontal lobe. Hypoperfusion in neurodegenerative states has pre-
viously been attributed to direct tissue loss or the result of loss of func-
tional connectivity (Borghammer et al., 2010; Yoshiura et al., 2009).We
feel that the small sample size may mean important differences be-
tween the 2 groups (such as hypoperfusion) which may be under-
represented in this study. Our results show that AAT is a more sensitivep value (IPD vs control) PIGD (n = 6) Tremor (n = 5)
0.1 6.4 (4.2) 3.6 (7.0)
0.6 −24.3 (3.7) −26.8 (1.8)
0.1 10 (2.9) 13.4 (1.5)
0.03 7.4 (1.6) 2.8 (0.6)
0.8 39.7 (24.2) 62.0 (22.8)
0.7 119.3 (43.7) 85.4 (31.4)
0.1 26.0 (3.3) 26.6 (2.7)
mbol substitution test; FAS VF, verbal ﬂuency; TMT-B, trial making test B;MoCA, Montreal
Table 6
Regions of signiﬁcant correlation between CBF and MoCA scores in the IPD group, thresholded to p b 0.001 uncorrected and minimum cluster size 100 voxels.
Region Cluster size Cluster p (FWE-cor) Peak t value Peak p value uncorrected Peak MNI coordinates
Left superior parietal lobe extending into precuneus and angular gyrus 464 0.09 6.1 b0.0001 −30−76 44
5.7 b0.0001 −40−70 42
5.4 b0.0001 −48−70 34
Left precuneus 112 0.6 5.7 b0.0001 −12−72 48
6 S. Al-Bachari et al. / NeuroImage: Clinical 6 (2014) 1–8marker of changes inNVS in IPD than CBF, andmay be important to con-
sider in future studies using ASL.
Despite diffuse baselineAAT prolongation in the IPD group, the glob-
al response of AAT and CBF to the hypercapnic challenge (CVR
AAT
and
CVR
CBF
) did not differ signiﬁcantly between the groups, suggesting vas-
cular responsiveness is generally preserved. If the prolonged baseline
AAT is indicative of chronic vasodilation then the AAT and CBF response
in the IPD groupwould be expected to be reduced (reduced capacity for
further dilation). However, the variability of both CVR
AAT
and CVR
CBF
is
large, so greater participant numbers are probably required to reliably
test for these differences.
This study also revealed a positive correlation between CBF predom-
inantly in the posterior regions and total MoCA scores in the IPD group.
This couldmean that hypoperfusion in these regions contributes to cog-
nitive impairment in IPD. Similarly cognitive scores including the mini
mental state examination (MMSE) scores and MoCA have been noted
to correlate with hypoperfusion in IPD and other diseases affecting cog-
nition, with speciﬁc patterns of hypoperfusion dependent on the dis-
ease state (Chao et al., 2010; Firbank et al., 2003; Nobili et al., 2008;
Yoon et al., 2012). However any potential causal relationship would
need further study. We recognise that the relatively small sample size
may potentially account for differences in other non-motor features
not reaching statistical signiﬁcance (Table 5) and further exploration
of their pathophysiological underpinnings is warranted.
This study did not reveal differences in WML burden between the
IPD group and controls; larger sample sizes would be needed to consid-
er phenotype-speciﬁc differences.
Certain limitations of this exploratory study must be acknowledged.
In particular, we used only 4 post-labelling time-points for the ASL ac-
quisition,whichwas necessary in order to cover the cerebrumwith vas-
cular crushing gradients enabled. More time points may have increased
the precision of the AAT measurements. Due to the exploratory natureFig. 2. Regions of signiﬁcant correlation between CBF and MoCA scores for the IPD grof the study, uncorrected p-values have been displayed alongside FWE
values, so a larger data set with FWE correction is required to verify
the results. It is possible that differences in NVS might be inﬂuential in
differing clinical phenotypes of IPD (Lee et al., 2009), however the
small sample size in this study meant that phenotype-speciﬁc differ-
ences could not be explored. LED scores differed between participants,
which may confound the results as previous studies have revealed
regional blood ﬂow increases with levodopa (Hershey et al., 2003;
Kobari et al., 1995).
5. Conclusion
This exploratory work used MRI perfusion and structural measures
to investigate NVS in IPD. In IPD we have identiﬁed prolonged baseline
AAT, as well as regional posterior hypoperfusion with correlations with
impaired cognition. Alterations in neurovascular parameters in IPD and
their associationswith clinical features and treatment, aswell as the po-
tential identiﬁcation of targets for intervention, warrant further study.
6. Appendix
ASL data were analysed using a single blood compartment model,
adapted for Look–Locker readout (Parkes L.M., 2012). This model as-
sumes that labelled water remains in the blood and that no labelled
water leaves the voxel, an approach that has been shown to be reason-
ably accurate (Parkes and Tofts, 2002).With these assumptions, the sig-
nal in the difference image (control – label), ΔM, can be described by:
dΔMðtÞ
dt
¼−R1ΔMðtÞ þ fmaðtÞ ð1Þoup, thresholded to p b 0.001 uncorrected and minimum cluster size 100 voxels.
7S. Al-Bachari et al. / NeuroImage: Clinical 6 (2014) 1–8where R1 is the apparent R1 of blood during the Look–Locker readout
and f is CBF. For STAR labelling themagnetisation of arterial blood,ma, is
given by:
maðtÞ ¼ 2m0aαexpðtR1bÞ f or t N taand t b τ ð2Þ
andma = 0 at all other times. Here, ta is the arrival time and τ is the
bolus width.Ma0 is the equilibrium magnetisation of arterial blood, α is
the inversion efﬁciency (assumed to equal 1) and R1b is the true R1 of
blood. According to Gunther et al. (2001) R1=R1b − ln(cosθ)/TI2
where θ is the ﬂip angle and TI
2
the spacing of the Look–Locker readout.
The solution for ΔM is:
ΔMðtÞ ¼ 2 fma
0α
ΔR
expðtR1Þ½expðtΔRÞ  expðtaΔRÞ f or tNtaand tbta þ τ
ð3Þ
ΔMðtÞ ¼ 2 fma
0α
ΔR
expðtR1ÞexpðtaΔRÞ½expðτΔRÞ  1 f or tNta þ τ
where ΔR = R1 − R1b. The mean difference signal ΔM was ﬁt on
a voxel-wise basis to Eq. 3, extracting values for the 2 free parameters
f (CBF) and ta (AAT), with ﬁxed values for τ = 1000 ms (MacIntosh
et al., 2010a), T
1b
= 1600 ms (Lu et al., 2004) (note R1b = 1/T1b), and
M0. The calibration images were ﬁt on a voxel-wise basis to a saturation
recovery curve, producing maps of T
1
andM0.Ma0 was estimated from a
whole brain estimate ofM0 divided by the blood–brain partition coefﬁ-
cient λ= 0.9 (Roberts et al., 1996).
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